文献速递白血病

PP2A 是通过 c-Myc/p21 轴驱动人和小鼠急性髓系白血病细胞命运决定的可治疗靶点

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
PubMed 文献 · Blood · 2022-01-01

该研究在人和小鼠急性髓系白血病(AML)中发现,蛋白磷酸酶 2A(PP2A)沉默直接阻断分化;使用新药 OSU-2S 联合遗传学方法证实 PP2A 激活通过 c-Myc 和 p21 依赖方式诱导终末分化、增殖停滞和凋亡,并在小鼠 Tet2-/-Flt3ITD/WT 及人细胞系来源异种移植 AML 模型中减少白血病起始干细胞、促进白血病原始细胞成熟并改善总生存。

要点

  • PP2A 沉默直接阻断 AML 细胞分化。
  • PP2A 激活通过 c-Myc/p21 轴诱导 AML 终末分化、增殖停滞和凋亡。
  • PP2A 激活在体内减少白血病起始干细胞并改善 AML 模型总生存。

核心结论

  • PP2A/c-Myc/p21 轴是 AML 中分化/增殖转换的关键调控轴,可作为成熟命运失调的恶性肿瘤的治疗靶点。

研究设计与样本

  • 研究采用基因表达和质谱流式细胞术分析,并使用新药 OSU-2S 联合遗传学方法,在人和小鼠 AML 模型中进行体外和体内实验。

主要发现

  • 基因表达和质谱流式细胞术分析显示,PP2A 激活调控细胞周期和转录调控因子,这些因子编程终末髓系分化。
  • 使用 OSU-2S 联合遗传学方法发现,PP2A 通过 c-Myc 和 p21 依赖方式强制 AML 终末分化、增殖停滞和凋亡。
  • 在 Tet2-/-Flt3ITD/WT 小鼠模型和人细胞系来源异种移植 AML 模型中,PP2A 激活减少白血病起始干细胞、增加白血病原始细胞成熟并改善总生存。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysregulated cellular differentiation is a hallmark of acute leukemogenesis. Phosphatases are widely suppressed in cancers but have not been traditionally associated with differentiation. In this study, we found that the silencing of protein phosphatase 2A (PP2A) directly blocks differentiation in acute myeloid leukemia (AML). Gene expression and mass cytometric profiling revealed that PP2A activation modulates cell cycle and transcriptional regulators that program terminal myeloid differentiation. Using a novel pharmacological agent, OSU-2S, in parallel with genetic approaches, we discovered that PP2A enforced c-Myc and p21 dependent terminal differentiation, proliferation arrest, and apoptosis in AML. Finally, we demonstrated that PP2A activation decreased leukemia-initiating stem cells, increased leukemic blast maturation, and improved overall survival in murine Tet2-/-Flt3ITD/WT and human cell-line derived xenograft AML models in vivo. Our findings identify the PP2A/c-Myc/p21 axis as a critical regulator of the differentiation/proliferation switch in AML that can be therapeutically targeted in malignancies with dysregulated maturation fate.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Goswami S, Mani R, Nunes J, et al. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood. 2022. PMID: 34788382. doi:10.1182/blood.2020010344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。